Trust Co. of Oklahoma Sells 1,409 Shares of Zoetis Inc. (NYSE:ZTS)

Trust Co. of Oklahoma reduced its stake in shares of Zoetis Inc. (NYSE:ZTS) by 16.9% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 6,947 shares of the company’s stock after selling 1,409 shares during the period. Trust Co. of Oklahoma’s holdings in Zoetis were worth $1,132,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Darwin Wealth Management LLC bought a new stake in Zoetis during the third quarter worth $31,000. First Personal Financial Services purchased a new position in Zoetis during the 3rd quarter worth $33,000. Capital Performance Advisors LLP bought a new stake in shares of Zoetis in the 3rd quarter worth $33,000. Dunhill Financial LLC raised its holdings in shares of Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after purchasing an additional 75 shares during the last quarter. Finally, Quarry LP lifted its position in shares of Zoetis by 273.2% during the second quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after purchasing an additional 153 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Trading Down 0.5 %

Shares of Zoetis stock opened at $166.64 on Thursday. The stock has a market capitalization of $75.18 billion, a P/E ratio of 31.32, a P/E/G ratio of 2.58 and a beta of 0.89. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.53. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The stock’s 50-day simple moving average is $170.39 and its 200 day simple moving average is $179.80.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.46 by $0.12. The company had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The company’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.36 earnings per share. As a group, research analysts anticipate that Zoetis Inc. will post 5.9 EPS for the current year.

Zoetis Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be given a $0.50 dividend. The ex-dividend date of this dividend is Tuesday, January 21st. This is a boost from Zoetis’s previous quarterly dividend of $0.43. This represents a $2.00 annualized dividend and a dividend yield of 1.20%. Zoetis’s payout ratio is 37.59%.

Wall Street Analysts Forecast Growth

ZTS has been the subject of a number of recent analyst reports. Leerink Partners started coverage on shares of Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price objective for the company. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Stifel Nicolaus dropped their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. UBS Group initiated coverage on Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective for the company. Finally, JPMorgan Chase & Co. boosted their price target on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. One research analyst has rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $211.89.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.